All In Biotech

Drug Trial Radar · NCT00657709

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Last checked: Nov 20, 2026Latest source record: Oct 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,630 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,630

Actual

Start

Mar 2008

Primary completion

Jan 2010

Study completion Jan 2010

Sponsor

Lead sponsor
Novartis VaccinesNovartis (NVS)
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Apr 14, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 55 days, up to 89 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The proposed study was aimed to assess the immunogenicity, safety, tolerability and lot to lot consistency of 3 lots of Novartis Meningococcal B vaccine when given concomitantly with routine infant vaccines.

Conditions

  • Serogroup B Meningococcal Meningitis

Interventions

  • Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)Biological

    One dose of rMenB Lot concomitantly with the routinely administered infant vaccines

  • Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)Biological

    One dose of rMenB concomitantly with the routinely administered infant vaccines

  • Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)Biological

    One dose of rMenB concomitantly with the routinely administered infant vaccines

  • Infanrix HexaBiological

    Routine vaccination

  • MenjugateBiological

    One dose of the routinely administered infant vaccines + MenC vaccine

  • PrevenarBiological

    Routine vaccination

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ VaccinationTime frame: one month after the third vaccination
  2. The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (3 Lots Combined)Time frame: one month after the third vaccination

Locations

66 sites in 5 countries. Site status is shown where the registry gives one.

  • Grässl

    Hall in Tirol, Austria

  • Häckel

    Kirchdorf, Austria

  • Prieler

    Neufeld A.d. Leitha, Austria

  • Maurer

    Salzburg, Austria

  • Sommer

    Vienna, Austria

  • Angermayr

    Wels, Austria

  • Site 27

    Boskovice, Czechia

  • Site 19

    Brno, Czechia

  • Site11

    Červený Kostelec, Czechia

  • Site 22

    Chomutov, Czechia

  • Site 14

    Děčín, Czechia

  • Site 12

    Havlíčkův Brod, Czechia

  • Site 8

    Hradec Králové, Czechia

  • Site 9

    Hradec Králové, Czechia

  • Site 28

    Hranice I-mesto, Czechia

  • Site 13

    Humpolec, Czechia

  • Site 15

    Jindřichův Hradec, Czechia

  • Site 25

    Kladno, Czechia

  • Site 21

    Kolín, Czechia

  • Site 10

    Liberec, Czechia

  • Site 24

    Litoměřice, Czechia

  • Site 17

    Ostrava, Czechia

  • Site 18

    Ostrava-Poruba, Czechia

  • Site 7

    Pardubice, Czechia

  • Site 16

    Pilsen, Czechia

  • Site 2

    Prague, Czechia

  • Site 3

    Prague, Czechia

  • Site 5

    Prague, Czechia

  • Site 6

    Prague, Czechia

  • Site 26

    Rumburk, Czechia

  • Site 23

    Ústí nad Labem, Czechia

  • Site 20

    Znojmo, Czechia

  • Site 30

    Espoo, Finland

  • Site 31

    Helsinki, Finland

  • Site 32

    Helsinki, Finland

  • Site 34

    Jarvenpaa, Finland

  • Site 35

    Kokkola, Finland

  • Site 45

    Kotka, Finland

  • Site 46

    Kuopio, Finland

  • Site 47

    Lahti, Finland

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.